Liraglutide suppresses obesity and induces brown fat-like phenotype via soluble guanylyl cyclase mediated pathway in vivo andin vitro
The 80-week trial was double-blinded, meaning neither the participants nor the researchers knew which treatment the participants received
GLP-1 receptor agonists (semaglutide, liraglutide) are MHRA-approved medications that lower blood glucose and promote weight loss by mimicking a natural hormone
Mechanism of Action: Triple Receptor Agonist Retatrutide is a synthetic peptide that activates three key metabolic receptors: GLP-1 (Glucagon-Like Peptide-1) Enhances insulin secretion, suppresses appetite, delays gastric emptying GIP (Glucose-Dependent Insulinotropic Polypeptide) Boosts insulin response, improves insulin sensitivity, may support lipid metabolism Glucagon Receptor (GCGR) Elevates energy expenditure, promotes fat oxidation, and may reduce liver fat This triple agonist profile delivers synergistic effects on glycemic control, fat loss, and metabolic health, making Retatrutide the most advanced incretin-based peptide in development
